Treatment of high-risk neuroblastoma with anti-GD2 antibodies

Clinical and Translational Oncology

Volumn 12, Issue 12, 2010, Pages 788-793

  Castel, Victoria ^a   Segura, Vanessa ^a   Cañete, Adela ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Anti GD2; Gangliosides; Immunotherapy; Neuroblastoma

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEUROBLASTOMA; RISK;

EID: 84855194547     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-010-0600-y     Document Type: Review

References (61)

1. Brodeur GM, Maris JM (2002) Neuroblastoma. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology, 4th Edn. JB Lippincott Williams & Wilkins, Philadelphia, pp 895-938.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369:2106-2120. (Pubitemid 46935947)
3. Castel V, Grau E, Noguera R, Martinez F (2007) Molecular biology of neuroblastoma. Clin Transl Oncol 9:478-483.
4. Barker E, Mueller BM, Handgretinger R et al (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51:144-149.
5. Reynolds CP, Seeger RC (2001) Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for highrisk neuroblastoma. J Pediatr Hematol Oncol 23:150-152. (Pubitemid 32332041)
6. Faulkner LB, Tamburini A, Tintori V et al (1998) [The identifi cation of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications]. Pediatr Med Chir 20:175-178.
7. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K (1986) Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol 102:688-696. (Pubitemid 16021888)
8. Svennerholm L, Bostrom K, Fredman P et al (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214:115-123. (Pubitemid 24287946)
9. Schulz G, Cheresh DA, Varki NM et al (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914-5920. (Pubitemid 15183611)
10. Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67-77. (Pubitemid 46423592)
11. Simon T, Hero B, Faldum A et al (2004) Consolidation treatment with chimeric anti-GD2-antibody Ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22:3549-3557. (Pubitemid 41103661)
12. Cheung NK, Kushner BH, LaQuaglia M et al (2001) N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 36:227- 230.
13. Nakamura K, Tanaka Y, Shitara K, Hanai N (2001) Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions. Cancer Immunol Immunother 50:275-284. (Pubitemid 32662531)
14. Navid F, Santana VM, Barfield RC (2010) Anti- GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 10:200-209.
15. Cheung NK, Yu AL (2000) Immunotherapy of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voûte PA (eds) Neuroblastoma. Elsevier Science, Amsterdam, pp 541-549.
16. Korec S, Herberman RB, Dean JH, Cannon GB (1980) Cytostasis of tumor cell lines by human granulocytes. Cell Immunol 53:104-115. (Pubitemid 10089850)
17. Vadas MA, Nicola NA, Metcalf D (1983) Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors. J Immunol 130:795-799.
18. Dallegri F, Patrone F, Frumento G, Sacchetti C (1984) Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst 73:331-339. (Pubitemid 14055212)
19. Steplewski Z, Sun LK, Shearman CW et al (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specifi city. Proc Natl Acad Sci U S A 85:4852-4856.
20. Kushner BH, Cheung NK (1989) GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941. (Pubitemid 19145127)
21. Bruchelt G, Handgretinger R, Fierlbeck G et al (1989) Lysis of neuroblastoma cells by the ADCC-reaction: granulocytes of patients with chronic granulomatous disease are more effective than those of healthy donors. Immunol Lett 22:217-220. (Pubitemid 19239454)
22. Cheung NK, Saarinen UM, Neely JE et al (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649. (Pubitemid 15024436)
23. Munn DH, Cheung NK (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47:6600-6605. (Pubitemid 18019663)
24. Munn DH, Garnick MB, Cheung NK (1990) Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood 75:2042-2048. (Pubitemid 20180295)
25. Cheung NK, Lazarus H, Miraldi FD et al (1987) Ganglioside GD2 specific monoclonal antibody 3f8: a phase i study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440. (Pubitemid 18049879)
26. Cheung NK, Kushner BH, Yeh SD, Larson SM (1998) 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol 12:1299-1306. (Pubitemid 28239940)
27. Cheung NK, Modak S (2002) Oral (1→3), (1→4)- beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217-1223. (Pubitemid 34517661)
28. Kushner BH, Kramer K, Cheung NK (2001) Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colonystimulating factor for neuroblastoma. J Clin Oncol 19:4189-4194. (Pubitemid 33081635)
29. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA (1987) Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098-1104. (Pubitemid 17027936)
30. Mujoo K, Kipps TJ, Yang HM et al (1989) Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 49:2857-2861. (Pubitemid 19148615)
31. Handgretinger R, Anderson K, Lang P et al (1995) A phase I study of human/mouse chimeric antiganglioside GD2 antibody Ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261-267.
32. Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL (1995) Pharmacokinetics of anti-ganglioside GD2 MAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother 41:29-36.
33. Gillies SD, Lo KM, Wesolowski J (1989) Highlevel expression of chimeric antibodies using adapted CDNA variable region cassettes. J Immunol Methods 125:191-202. (Pubitemid 20018022)
34. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA (1990) Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 144:1382-1386. (Pubitemid 20072910)
35. Yu AL, Uttenreuther-Fischer MM, Huang CS et al (1998) Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody Ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16:2169-2180. (Pubitemid 28265055)
36. Kremens B, Hero B, Esser J et al (2002) Ocular symptoms in children treated with human-mouse chimeric anti-GD2 MAb Ch14.18 for neuroblastoma. Cancer Immunol Immunother 51:107-110. (Pubitemid 34230725)
37. Ozkaynak MF, Sondel PM, Krailo MD et al (2000) Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (Ch14.18) with granulocyte-macrophage colonystimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 18:4077-4085. (Pubitemid 32038400)
38. Gilman AL, Ozkaynak MF, Matthay KK et al (2009) Phase I study of Ch14.18 with granulocyte- macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stemcell rescue: a report from the Children's Oncology Group. J Clin Oncol 27:85-91.
39. Yu AL, Batova A, Gribi R et al (2004) A phase III randomized trial of chimeric anti-GD2 and GMCSF/IL2 in high-risk neuroblastoma following myeloablative therapy and autologous stem cell transplant (ASCT). Proc Am Soc Clin Oncol 23:183.
40. Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334.
41. Lode HN, Xiang R, Dreier T et al (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin- 2 therapy. Blood 91:1706-1715.
42. Ladenstein R, Valteau-Couanet D, Brock P et al (2010) Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with highrisk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 28:3516-3524.
43. Fest S, Huebener N, Weixler S et al (2006) Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66:10567-10575. (Pubitemid 44799780)
44. Schwinger W, Klass V, Benesch M et al (2005) Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann Oncol 16:1199-1206. (Pubitemid 41418325)
45. Russell HV, Strother D, Mei Z et al (2008) A phase 1/2 study of autologous neuroblastoma tumor cells genetically modifi ed to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 31:812-819.
46. Gillies SD, Reilly EB, Lo KM, Reisfeld RA (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A 89:1428-1432.
47. Hank JA, Surfus JE, Gan J et al (1996) Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (Ch14.18-IL2). Clin Cancer Res 2:1951-1959. (Pubitemid 27006627)
48. Osenga KL, Hank JA, Albertini MR et al (2006) A phase i clinical trial of the Hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 12:1750-1759.
49. Neal ZC, Yang JC, Rakhmilevich AL et al (2004) Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10:4839-4847. (Pubitemid 38955538)
50. Uttenreuther-Fischer MM, Kruger JA, Fischer P (2006) Molecular characterization of the antiidiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin? J Immunol 176:7775-7786. (Pubitemid 43849079)
51. Yan X, Johnson BD, Orentas RJ (2008) Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol 181:4621-4631.
52. Kowalczyk A, Wierzbicki A, Gil M et al (2007) Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol Immunother 56:1443-1458. (Pubitemid 47024709)
53. Russell HV, Strother D, Mei Z et al (2007) Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modifi ed to secrete IL-2 and lymphotactin. J Immunother 30:227-233. (Pubitemid 46667802)
54. Pertl U, Wodrich H, Ruehlmann JM et al (2003) Immunotherapy with a posttranscriptionally modifi ed DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101:649-654. (Pubitemid 36077589)
55. Cheung NK, Burch L, Kushner BH, Munn DH (1991) Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a phase II trial. Prog Clin Biol Res 366:395-400.
56. Cheung NK, Kushner BH, Cheung IY et al (1998) Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16:3053-3060. (Pubitemid 28417426)
57. Kramer K, Gerald WL, Kushner BH et al (1998) Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Cancer Res 4:2135-2139. (Pubitemid 28415659)
58. Kushner BH, Kramer K, LaQuaglia MP et al (2003) Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering Experience. Med Pediatr Oncol 41:508-515. (Pubitemid 37386067)
59. Handgretinger R, Baader P, Dopfer R et al (1992) A phase I study of neuroblastoma with the antiganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199-204.
60. Murray JL, Cunningham JE, Brewer H et al (1994) Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193. (Pubitemid 24020639)
61. Frost JD, Hank JA, Reaman GH et al (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80:317-333. (Pubitemid 27282327)